Travoprost Ophthalmic Solution USP, 0.004%, is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.
The project funding will be done through a mix of internal accruals and debts.
The brand has also unveiled a new TVC campaign in Telangana and Andhra Pradesh to drive brand awareness
GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)
TIVDAK is the first antibody-drug conjugate (ADC) to have positive overall survival data for patients with previously treated recurrent or metastatic cervical cancer
First-quarter 2024 revenues totaled $14.9 billion, a decrease of $3.6 billion, or 20%, compared to the prior-year quarter
The CALINA study tested a new ratio and dose of Coartem to account for metabolic differences in babies under 5 kg
2024 full-year revenue guidance raised by US$ 2 billion
Colchicine Capsules are indicated for prophylaxis of gout flares in adult
New advanced technology-enabled offering aims to streamline synthetic route identification for novel active pharmaceutical ingredients (APIs)
Subscribe To Our Newsletter & Stay Updated
